Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Bictegravir (BIC; GS-9883), a novel, potent, once-daily, unboosted inhibitor of HIV-1 integrase (IN), specifically targets IN strand transfer activity (50% inhibitory concentration [IC 50] of 7.5 ± 0.3 nM) and HIV-1 integration in cells. BIC exhibits potent and selective in vitro antiretroviral activity in both T-cell lines and primary human T lymphocytes, with 50% effective concentrations ranging from 1.5 to 2.4 nM and selectivity indices up to 8,700 relative to cytotoxicity. BIC exhibits synergistic in vitro antiviral effects in pairwise combinations with tenofovir alafenamide, emtricitabine, or darunavir and maintains potent antiviral activity against HIV-1 variants resistant to other classes of antiretrovirals. BIC displayed an in vitro resistance profile that was markedly improved compared to the integrase strand transfer inhibitors (INSTIs) raltegravir (RAL) and elvitegravir (EVG), and comparable to that of dolutegravir (DTG), against nine INSTI-resistant site-directed HIV-1 mutants. BIC displayed statistically improved antiviral activity relative to EVG, RAL, and DTG against a panel of 47 patient-derived HIV-1 isolates with high-level INSTI resistance; 13 of 47 tested isolates exhibited >2-fold lower resistance to BIC than DTG. In dose-escalation experiments conducted in vitro, BIC and DTG exhibited higher barriers to resistance than EVG, selecting for HIV-1 variants with reduced phenotypic susceptibility at days 71, 87, and 20, respectively. A recombinant virus with the BIC-selected M50I/R263K dual mutations in IN exhibited only 2.8-fold reduced susceptibility to BIC compared to wild-type virus. All BIC-selected variants exhibited low to intermediate levels of cross-resistance to RAL, DTG, and EVG (<8-fold) but remained susceptible to other classes of antiretrovirals. A high barrier to in vitro resistance emergence for both BIC and DTG was also observed in viral breakthrough studies in the presence of constant clinically relevant drug concentrations. The overall virologic profile of BIC supports its ongoing clinical investigation in combination with other antiretroviral agents for both treatment-naive and -experienced HIV-infected patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the last 14 years, four more INSTIs were approved for treatment of HIV infection: elvitegravir, dolutegravir, bictegravir and cabotegravir147–150.”
From Structure and function of retroviral integrase (2022) · cites this paper as [149]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Walmsley, S. L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215541 · Cited by 876
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708975 · Cited by 691
A quantitative assay for HIV DNA integration in vivo
Butler, S. L., Hansen, M. S. T., & Bushman, F. D. (2001) · Nature Medicine · doi:10.1038/87979 · Cited by 687
A three-dimensional model to analyze drug-drug interactions
Prichard, M. N., & Shipman, C. (1990) · Antiviral Research · doi:10.1016/0166-3542(90)90001-n · Cited by 544
Cahn, P., Pozniak, A. L., Mingrone, H., Shuldyakov, A., Brites, C., Andrade-Villanueva, J. F., Richmond, G., Buendia, C. B., Fourie, J., Ramgopal, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61221-0 · Cited by 516
Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
Cooper, D. A., Steigbigel, R. T., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Kumar, P. N., Eron, J. E., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708978 · Cited by 509
Clotet, B., Feinberg, J., van Lunzen, J., Khuong-Josses, M.-A., Antinori, A., Dumitru, I., Pokrovskiy, V., Fehr, J., Ortiz, R., Saag, M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60084-2 · Cited by 507
In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
Kobayashi, M., Yoshinaga, T., Seki, T., Wakasa-Morimoto, C., Brown, K. W., Ferris, R., Foster, S. A., Hazen, R. J., Miki, S., Suyama-Kagitani, A., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01209-10 · Cited by 382
Raffi, F., Jaeger, H., Quiros-Roldan, E., Albrecht, H., Belonosova, E., Gatell, J. M., Baril, J.-G., Domingo, P., Brennan, C., Almond, S., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70257-3 · Cited by 379
Shimura, K., Kodama, E., Sakagami, Y., Matsuzaki, Y., Watanabe, W., Yamataka, K., Watanabe, Y., Ohata, Y., Doi, S., Sato, M., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01534-07 · Cited by 343
Research works printed but not linked: 7
- Lepik KJ, Yip B, Robbins M, Woods C, Lima VD, McGovern RA, Zhang WW, Barrios R, Montaner JSG, Harrigan PR. 2016. Prevalence and incidence of integrase drug resistance in BC, Canada 2009-2015. Abstr 23rd Conf Retroviruses Opportunistic Infect, abstr 492LB.
- ViiV Healthcare. 2015. Tivicay 50 mg film-coated tablets. ViiV Healthcare, Middlesex, United Kingdom.
- Lazerwith SE, Cai R, Chen X, Desai MC, Eng S, Jacques R, Ji M, Martin H, McMahon C, Mish M, Morganelli P, Mwangi J, Pyun HJ, Schmitz U, Stepan G, Szwarcberg J, Tang J, Tsiang M, Wang J, White K, Wiser L, Zack J, Jin H. 2016. Discovery of bictegravir (GS-9883), a novel, unboosted, once-daily HIV-1 integrase strand transfer inhibitor (INSTI) with improved pharmacokinetics and in vitro resistance profile. ASM Microbe 2016, poster 414.
- Pozniak A, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Hagins D, Buendia CB, Dorey D, Griffith S, Min S. Dolutegravir (DTG) versus raltegravir (RAL) in ART-experienced, integrase-naive subjects: 24 week interim results from SAILING (ING111762). Abstr 20th Conf Retroviruses Opportunistic Infect, abstr 179LB.
- Jones G, Ledford RM, Yu F, Chen X, Miller MD, Tsiang M, McColl DJ. In vitro resistance profile of HIV-1 mutants selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). Abstr 14th Conf Retroviruses Opportunistic Infect, abstr 627.
- Abram M, Margot N, Barnes T, Ram R, Chen X, White K, Miller M, Callebaut C. 2014. Clinical impact and characterization of HIV integrase inhibitor resistance associated with T97A: a low-level polymorphic integrase mutation, abstr POH-017. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
- 10.1310/hct1504-218 · DOI
Cited by
Items 101–200 of 331
Gaur, A. H., Cotton, M. F., Rodriguez, C. A., McGrath, E. J., Hellström, E., Liberty, A., Natukunda, E., Kosalaraksa, P., Chokephaibulkit, K., Maxwell, H., et al. (2020) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(21)00165-6 · Cited by 25
Esposito, F., Sechi, M., Pala, N., Sanna, A., Koneru, P. C., Kvaratskhelia, M., Naesens, L. M. J., Corona, A., Grandi, N., Santo, R. D., et al. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.104671 · Cited by 24
Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance
Richetta, C., Tu, N. Q., & Delelis, O. (2022) · Viruses · doi:10.3390/v14122591 · Cited by 24
Investigational HIV integrase inhibitors in phase I and phase II clinical trials
Han, Y.-S., Mésplède, T., & Wainberg, M. A. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1378643 · Cited by 24
Scutari, R., Alteri, C., Vicenti, I., Carlo, D. D., Zuccaro, V., Incardona, F., Borghi, V., Bezenchek, A., Andreoni, M., Antinori, A., et al. (2019) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2019.07.015 · Cited by 24
Xiao, M. A., Cleyle, J., Yoo, S., Forrest, M., Krullaars, Z., Pham, H. T., & Mésplède, T. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01386-22 · Cited by 23
Update On HIV Integrase Inhibitors for the Treatment of HIV-1 Infection
Max, B. E. (2019) · Future Virology · doi:10.2217/fvl-2019-0077 · Cited by 23
Smith, S. J., Zhao, X. Z., Passos, D. O., Pye, V. E., Cherepanov, P., Lyumkis, D., Burke, T. R., & Hughes, S. H. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00819 · Cited by 22
Saladini, F., Giannini, A., Boccuto, A., Dragoni, F., Appendino, A., Albanesi, E., Vicenti, I., & Zazzi, M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01717-19 · Cited by 22
Pham, H. T., & Mésplède, T. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1560423 · Cited by 22
Huang, X., Luo, R., Hu, X.-L., Chen, H., Xiang, S.-Y., Tang, C.-R., Zhang, C., Shen, X.-N., & Zheng, Y. (2020) · Current HIV Research · doi:10.2174/1570162x18666200620211922 · Cited by 22
Hill, L. A., Smith, S. R., & Karris, M. (2018) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s145529 · Cited by 22
First pharmacokinetic data of bictegravir in pregnant women living with HIV
Bukkems, V. E., Hidalgo-Tenorio, C., García, C., van Hulzen, A. G. W., Richel, O., Burger, D. M., & Colbers, A. P. H. (2021) · AIDS · doi:10.1097/qad.0000000000003032 · Cited by 22
Bekerman, E., Cox, S., Babusis, D. M., Campigotto, F., Das, M., Barouch, D. H., Cihlář, T., & Callebaut, C. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa476 · Cited by 21
Pennetzdorfer, N., Naik, V., Demirdjian, S., Hendricks, M. R., Jamieson, C. S., Perry, J. K., VanderVeen, L. A., Yant, S. R., Dvory‐Sobol, H., Ogbuagu, O. E., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aea0947 · Cited by 21
Self-citationClinical experience with integrase inhibitors in HIV-2-infected individuals in Spain
Requena, S., Lozano, A. B., Caballero, E., García, F., Nieto, M. C., Téllez, R., Fernández, J. M., Trigo, M., Rodríguez-Avial, I., Martín‐Carbonero, L., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz007 · Cited by 21
Yinghua, W., Li, J., Xu, R., Li, W., Deng, Y., He, L., Zhong, H., & Wang, Y. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002907 · Cited by 21
Marcelin, A., Grudé, M., Charpentier, C., Bellecave, P., Guen, L. L., Pallier, C., Raymond, S., Mirand, A., Bocket, L., Fofana, D., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz021 · Cited by 21
Barski, M. S., Vanzo, T., Zhao, X. Z., Smith, S. J., Ballandras-Colas, A., Cronin, N., Pye, V. E., Hughes, S. H., Burke, T. R., Cherepanov, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25284-1 · Cited by 20
Antiretroviral resistance testing in HIV-positive people
Aves, T., Tambe, J., Siemieniuk, R. A. C., & Mbuagbaw, L. C. E. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006495.pub5 · Cited by 20
Four Decades of HIV: Global Trends, Testing Assays, Treatment, and Challenges
Haris, M., & Abbas, R. (2024) · Zoonoses · doi:10.15212/zoonoses-2023-0039 · Cited by 20
Acosta, R. K., Chen, G. Q., Chang, S., Martin, R., Wang, X., Huang, H., Brainard, D. M., Collins, S. E., Martin, H., & White, K. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab115 · Cited by 20
Self-citationHuman Immunodeficiency Virus Type 1 Drug Resistance Mutations Update
Shafer, R. W. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix398 · Cited by 20
Liou, B., Cheng, C., Lin, Y., Lin, Y., Chuang, Y., Lin, K., Liu, W., Lin, S., Kuo, C., Sun, H., et al. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25844 · Cited by 19
Tiraboschi, J. M., Imaz, A., Khoo, S., Niubó, J., Prieto, P., Saumoy, M., Penchala, S. D., García, B., Padilla, C., Videla, S., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz624 · Cited by 19
Mandal, S., Prathipati, P. K., Sunagawa, S. W., & Destache, C. J. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02320-20 · Cited by 18
Mugisha, C. S., Dinh, T., Kumar, A., Tenneti, K., Eschbach, J. E., Davis, K., Gifford, R. J., Kvaratskhelia, M., & Kutluay, S. B. (2022) · mBio · doi:10.1128/mbio.00431-22 · Cited by 18
Schafer, J. J., Pandit, N. S., Cha, A., Huesgen, E. C., Badowski, M. E., Sherman, E. M., Cocohoba, J. M., Shimada, A., & Keith, S. W. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa625 · Cited by 18
Biological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase
Bonnard, D., Rouzic, E. L., Singer, M. R., Yu, Z., Strat, F. L., Batisse, C., Batisse, J., Amadori, C., Chasset, S., Pye, V. E., et al. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00462-23 · Cited by 17
Ndashimye, E., Li, Y., Reyes, P. S., Avino, M., Olabode, A. S., Kityo, C. M., Kyeyune, F., Nankya, I., Quiñones‐Mateu, M. E., Barr, S. D., et al. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab276 · Cited by 17
Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters
Corona‐Mata, D., Valero, I., Camacho, Á., Gutiérrez, Á., Montero, M., Valls, M. R. A., Ruíz-Seco, P., Pérez‐González, A., Riera, M., Jarrín, I., et al. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.107016 · Cited by 17
Casadellà, M., Santos, J. R., Noguera-Julián, M., Micán-Rivera, R., Domingo, P., Antela, A., Portilla, J., Sanz, J., Montero, M., Navarro, J., et al. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa349 · Cited by 17
Muzalevskiy, V. M., Sizova, Z. A., Belyaeva, K. V., Trofimov, B. A., & Nenajdenko, V. G. (2019) · Molecules · doi:10.3390/molecules24193594 · Cited by 16
Santoro, M. M., Fornabaio, C., Malena, M., Galli, L., Poli, A., Menozzi, M., Zazzi, M., White, K., & Castagna, A. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106027 · Cited by 15
Self-citationCheung, P. K., Shahid, A., Dong, W. W. Y., Lepik, K. J., Montaner, J. S. G., Brockman, M. A., Brumme, Z. L., & Brumme, C. J. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab498 · Cited by 15
HIV Glasgow, 23–26 October 2022, Glasgow, UK / Virtual
Akalin, E., Birengel, M. S., Yıldırmak, T., Demırdal, T., Eraksoy, Ö. H., Karaoğlan, İ., Asuman, İ., Deveci, A., Özdemir, H. Ö., Gökengin, A. D., et al. (2022) · Journal of the International AIDS Society · doi:10.1002/jia2.26009 · Cited by 15
INSTIs and NNRTIs Potently Inhibit HIV-1 Polypurine Tract Mutants in a Single Round Infection Assay
Smith, S. J., Ferris, A. L., Zhao, X. Z., Pauly, G. T., Schneider, J. P., Burke, T. R., & Hughes, S. H. (2021) · Viruses · doi:10.3390/v13122501 · Cited by 15
Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs
Gantner, P., Lee, G. Q., Rey, D., Mésplède, T., Partisani, M., Cheneau, C., Beck-Wirth, G., Faller, J.-P., Mohseni-Zadeh, M., Martinot, M., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx475 · Cited by 15
Patel, M., Cianci, C., Allard, C. W., Parker, D. D., Simmermacher, J., Jenkins, S., McAuliffe, B. V., Minassian, B., Discotto, L. F., Krystal, M., et al. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127516 · Cited by 15
Rodriguez, C. A., Natukunda, E., Strehlau, R., Venter, E. L., Rungmaitree, S., Cunningham, C. K., Lalloo, U., Kosalaraksa, P., Hellström, E., Liberty, A., et al. (2024) · The Lancet HIV · doi:10.1016/s2352-3018(23)00327-2 · Cited by 15
1,3-Amino alcohols and their phenol analogs in heterocyclization reactions
Palchykov, V. A., & Gaponov, A. A. (2019) · Advances in heterocyclic chemistry · doi:10.1016/bs.aihch.2019.06.001 · Cited by 15
Andreatta, K. N., Sax, P. E., Wohl, D., D’Antoni, M. L., Liu, H., Hindman, J. T., & Callebaut, C. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae407 · Cited by 14
Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavir
Hansen, D., Hendricks, M. R., Chang, S., Cai, A., Perry, J. K., Aeschbacher, T., Martin, R., Cihlář, T., & Yant, S. R. (2025) · mBio · doi:10.1128/mbio.00187-25 · Cited by 14
Self-citationBRENNER, B. G., Ibanescu, R.-I., Oliveira, M., Roger, M., Hardy, I., Routy, J., Kyeyune, F., Quiñones‐Mateu, M. E., Wainberg, M. A., & on behalf of the Montreal PHI Cohort Study Group (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx118 · Cited by 14
Initial Antiretroviral Therapy in an Integrase Inhibitor Era
Kelly, S. G., Masters, M. C., & Taiwo, B. (2019) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2019.05.003 · Cited by 14
Andreatta, K. N., D’Antoni, M. L., Chang, S., Parvangada, A., Martin, R., Blair, C. J., Hagins, D. P., Kumar, P. N., Hindman, J. T., Martin, H., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29899 · Cited by 14
Tanuja, A., & Ganapaty, S. (2022) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.56.4.201 · Cited by 14
Lazzaro, A., Bianchini, D., Cacciola, E. G., Mezzaroma, I., Falciano, M., Andreoni, C., Fimiani, C., Santinelli, L., Maddaloni, L., Bugani, G., et al. (2023) · Viruses · doi:10.3390/v15061222 · Cited by 14
DeKoven, S. J., Naccarato, M., Brumme, C. J., & Tan, D. H. S. (2023) · HIV Medicine · doi:10.1111/hiv.13520 · Cited by 14
Singh, P., Li, W., Bedwell, G., Fadel, H., Poeschla, E., & Engelman, A. (2022) · Viruses · doi:10.3390/v14091883 · Cited by 13
Xu, P., Zhu, L., Zhang, D., Li, Z., Ge, R., & Tian, Q. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101446 · Cited by 13
Rashamuse, T. J., Fish, M. Q., Coyanis, E. M., & Bode, M. L. (2021) · Molecules · doi:10.3390/molecules26206203 · Cited by 13
Orkin, C. M., Ajana, F., Kityo, C. M., Koenig, E., Natukunda, E., Gandhi‐Patel, B., Wang, H., Liu, Y., Wei, X., White, K., et al. (2021) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002789 · Cited by 13
Self-citationPatel, M., Naidu, B. N., Dicker, I. B., Higley, H., Lin, Z., Terry, B., Protack, T., Krystal, M., Jenkins, S., Parker, D. D., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115541 · Cited by 13
Mulato, A. S., Acosta, R. K., Chang, S., Martin, R., Yant, S. R., Cihlář, T., & White, K. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002562 · Cited by 13
Self-citationSavioli, N. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2004.02136 · Cited by 12
The Integrase: An Overview of a Key Player Enzyme in the Antiviral Scenario
Renzi, G., Carta, F., & Supuran, C. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512187 · Cited by 12
Engelman, A., & Cherepanov, P. (2020) · FEBS Journal · doi:10.1111/febs.15438 · Cited by 12
Acosta, R. K., D’Antoni, M. L., Mulato, A. S., Yant, S. R., Cihlář, T., & White, K. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02038-21 · Cited by 12
Self-citationD’Antoni, M. L., Andreatta, K. N., Acosta, R. K., Martin, H., Chang, S., Martin, R., & White, K. (2021) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002888 · Cited by 12
Self-citationIntegrase inhibitors: current protagonists in antiretroviral therapy
Loaiza, J. D., Chvatal‐Medina, M., Hernández, J. C., & Rugeles, M. T. (2023) · Immunotherapy · doi:10.2217/imt-2023-0011 · Cited by 11
Structural Insights on Retroviral DNA Integration: Learning from Foamy Viruses
Lee, G.-E., Mauro, E., Parissi, V., Shin, C., & Lesbats, P. (2019) · Viruses · doi:10.3390/v11090770 · Cited by 11
A medicinal chemistry overview of direct-acting antivirals approved in 2013–2024 by US FDA
Nizi, M. G., Massari, S., Tabarrini, O., & Manfroni, G. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118105 · Cited by 11
The clinical pharmacology of integrase inhibitors
Perri, G. D., Calcagno, A., Trentalange, A., & Bonora, S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1553615 · Cited by 11
Xue, W., Zhu, F., Yang, F., Yang, J., Zhang, Z., Tu, G., & Yao, X. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210708090123 · Cited by 11
Sai Krishna, A. V. S., Sinha, S., & Donakonda, S. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.07.040 · Cited by 11
Zaongo, S. D., Wang, Y., Ma, P., Song, F., & Chen, Y.-K. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001797 · Cited by 11
The crosstalk between antiretrovirals pharmacology and HIV drug resistance
Giacomelli, A., Pezzati, L., & Rusconi, S. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1782737 · Cited by 11
Digban, T. O., Iweriebor, B. C., Chikwelu, L., Nwodo, U. U., & Okoh, A. I. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25661 · Cited by 11
Parczewski, M., Leszczyszyn‐Pynka, M., & Urbańska, A. (2016) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2016.12.019 · Cited by 11
Gelé, T., Chéret, A., Gordon, A. C., Nkam, L., Furlan, V., Pallier, C., Becker, P., Catalan, P., Goujard, C., Taburet, A., et al. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab334 · Cited by 11
Ke, D., Zhang, L., Zhong, X., Shao, J., Yu, Y., & Chen, W. (2022) · Organic Letters · doi:10.1021/acs.orglett.1c03833 · Cited by 11
HIV-1 non-group M phenotypic susceptibility in vitro to bictegravir and cabotegravir
Martin, C., Gracias, S., Charpentier, C., Descamps, D., Hingrat, Q. L., Plantier, J., & Alessandri-Gradt, É. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab196 · Cited by 11
Strain-specific effect on biphasic DNA binding by HIV-1 integrase
Hill, K. J., Rogers, L. C., Njenda, D. T., Burke, D. H., Sarafianos, S. G., Sönnerborg, A. B., Neogi, U., & Singh, K. (2018) · AIDS · doi:10.1097/qad.0000000000002078 · Cited by 10
Discovery of Small-Molecule Orthopoxvirus Resolvase Inhibitors with Antiviral Activity
Mahoney, J. P., Offei, S. D., Pant, A., Wang, Z., Weiner, B., Yin, L., Ryu, W. H., Katekar, R. A., Williams, J. M., Aihara, H., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00019 · Cited by 10
Wang, L., Edwards, T. C., Sahani, R. L., Xie, J., Aihara, H., Geraghty, R. J., & Wang, Z. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113640 · Cited by 10
Machado, L. D. A., Gomes, M. F. D. C., & Guimarães, A. C. R. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01981 · Cited by 10
Comprehensive database of HIV mutations selected during antiretroviral in vitro passage experiments
Tao, K., Zhou, J., Nagarajan, P., Tzou, P. L., & Shafer, R. W. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105988 · Cited by 10
HIV-1 integrase drug-resistance mutations in Iranian treatment-experienced HIV-1-infected patients
Marjani, A., Bokharaei‐Salim, F., Jahanbakhshi, F., Monavari, S. H., Esghaei, M., Kalantari, S., Kiani, S. J., Ataei‐Pirkooh, A., Fakhim, A., & Keyvani, H. (2019) · Archives of Virology · doi:10.1007/s00705-019-04463-y · Cited by 10
Frange, P., Veber, F., Burgard, M., Blanche, S., & Avettand-Fènoël, V. (2023) · HIV Medicine · doi:10.1111/hiv.13562 · Cited by 10
Diesel, J., & Cramer, N. (2020) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2020.278 · Cited by 10
HIV integrase inhibitors that inhibit strand transfer interact with RAG1 and hamper its activities
Nilavar, N. M., & Raghavan, S. C. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107515 · Cited by 9
An Update on Antiretroviral Therapy
Menéndez‐Arias, L., Martín-Alonso, S., & Frutos-Beltrán, E. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-16-0267-2_2 · Cited by 9
Metal coordinating inhibitors of Rift Valley fever virus replication
Geerling, E., Murphy, V., Mai, M. C., Stone, E. T., Casals, A. G., Hassert, M., O’Dea, A. T., Cao, F., Donlin, M. J., Elagawany, M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274266 · Cited by 9
Nakamura, T., Okumura, M., Takamune, N., Hirotsu, T., Sugiura, M., Yasunaga, J., & Nakata, H. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad446 · Cited by 9
Subramanian, R., Wang, J., Murray, B. P., Custodio, J. M., Hao, J., Lazerwith, S. E., Staiger, K. M., Mwangi, J. W., Sun, H., Tang, J. C., et al. (2022) · Xenobiotica · doi:10.1080/00498254.2023.2169207 · Cited by 9
Self-citationHIV-1 Non-Group M Strains and ART
Alessandri-Gradt, É., Moisan, A., & Plantier, J. (2023) · Viruses · doi:10.3390/v15030780 · Cited by 9
Valero, I., Corona‐Mata, D., Espejo, Á. C., Gallo, M., de Morales, A. G. G.-R., Fanciulli, C., Martín‐Carbonero, L., Calzado, S., Gutiérrez, C. H., Asensi, V., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf162 · Cited by 9
Mulato, A. S., Lansdon, E. B., Aoyama, R. G., Voigt, J. H., Lee, M., Liclican, A. C., Lee, G., Singer, E. A., Stafford, B., Gong, R., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01373-23 · Cited by 9
Self-citationSimplifying ARV Therapy in the Setting of Resistance
Pandit, N. S., Chastain, D. B., Pallotta, A. M., Badowski, M. E., Huesgen, E. C., & Michienzi, S. M. (2019) · Current Infectious Disease Reports · doi:10.1007/s11908-019-0691-8 · Cited by 9
Musat, M., Nițulescu, G. M., Surleac, M. D., Tsatsakis, A. M., Spandidos, D. A., & Margina, D. M. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10777 · Cited by 8
Brief Histories of Retroviral Integration Research and Associated International Conferences
Grandgenett, D. P., & Engelman, A. (2024) · Viruses · doi:10.3390/v16040604 · Cited by 8
Machado, L. D. A., & Guimarães, A. C. R. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00170 · Cited by 8
Identification and Optimization of a Novel HIV-1 Integrase Inhibitor
Adu‐Ampratwum, D., Pan, Y., Koneru, P. C., Antwi, J., Hoyte, A. C., Kessl, J. J., Griffin, P. R., Kvaratskhelia, M., Fuchs, J. R., & Larue, R. C. (2022) · ACS Omega · doi:10.1021/acsomega.1c06378 · Cited by 8
Choy, C. Y., Wong, C. S., Kumar, P. A., Olszyna, D. P., Teh, Y. E., Chien, M. F. J., Kurup, A., Koh, Y. L., Ho, L. P., Law, H. L., et al. (2022) · Singapore Medical Journal · doi:10.11622/smedj.2021174 · Cited by 8
Cento, V., & Perno, C. F. (2021) · Diagnostics · doi:10.3390/diagnostics11050809 · Cited by 8
A Pharmacokinetic Dose-Optimization Study of Cabotegravir and Bictegravir in a Mouse Pregnancy Model
Mohan, H., Atkinson, K., Watson, B. E., Brumme, C. J., & Serghides, L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091761 · Cited by 8
Sax, P. E., DeJesus, E., Crofoot, G. E., Ward, D. J., Benson, P. M., Dretler, R. H., Mills, A., Brinson, C. C., Wei, X., Collins, S. E., et al. (2018) · AIDS · doi:10.1097/qad.0000000000001894 · Cited by 8
Iwuji, C. C., Churchill, D. R., Bremner, S. A., Perry, N., To, Y., Lambert, D., Bruce, C., Waters, L. J., Orkin, C. M., & Geretti, A. M. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05240-y · Cited by 7
New designs for HIV-1 integrase inhibitors: a patent review (2018-present)
Taoda, Y., Sugiyama, S., & Seki, T. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2178300 · Cited by 7
Metadata
- Authors
- Tsiang, M., Jones, G. S., Goldsmith, J., Mulato, A., Hansen, D., Kan, E., Tsai, L., Bam, R. A., Stepan, G., Stray, K. M., Niedziela-Majka, A., Yant, S. R., Yu, H., Kukolj, G., Cihlar, T., Lazerwith, S. E., White, K. L., & Jin, H.
- Affiliations
- Gilead Sciences (United States) (US)
- Gilead Sciences, Foster City, California, USA
- Corresponding author
- White, Kirsten L.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2016-12
- Volume
- 60
- Issue
- 12
- Pages
- 7086-7097
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC5118987
- OpenAlex
- W2523305619
- Cited by
- 290
- References
- 50
- Citations by year
- 2026: 19 · 2025: 26 · 2024: 24 · 2023: 25 · 2022: 24 · 2021: 40 · 2020: 37 · 2019: 38 · 2018: 36 · 2017: 18 · 2016: 2
- FWCI
- 28.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- bictegravir, antiviral activity, drug resistance, integrase inhibitors, dolutegravir, raltegravir, elvitegravir, cross-resistance, viral breakthrough, tenofovir alafenamide, emtricitabine, darunavir, drug selectivity
- MeSH terms
- Raltegravir Potassium, Dolutegravir, Amides, Cell Line, Drug Synergism, Heterocyclic Compounds, 3-Ring, Heterocyclic Compounds, 4 or More Rings, Humans, Mutation, Oxazines, Piperazines, Pyridones, HIV-1, Anti-HIV Agents, HIV Integrase, HIV Integrase Inhibitors, Drug Resistance, Viral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.